Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Debt (2016 - 2025)

Historic Total Debt for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $316.1 million.

  • ImmunityBio's Total Debt rose 1552.6% to $316.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.1 million, marking a year-over-year increase of 1552.6%. This contributed to the annual value of $284.4 million for FY2024, which is 8299.65% up from last year.
  • Per ImmunityBio's latest filing, its Total Debt stood at $316.1 million for Q3 2025, which was up 1552.6% from $307.0 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Total Debt registered a high of $480.0 million during Q3 2023, and its lowest value of $155.4 million during Q4 2023.
  • Moreover, its 5-year median value for Total Debt was $307.0 million (2025), whereas its average is $295.9 million.
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 3684056.27% in 2021, then crashed by 4299.05% in 2024.
  • Over the past 5 years, ImmunityBio's Total Debt (Quarter) stood at $306.3 million in 2021, then increased by 21.85% to $373.3 million in 2022, then tumbled by 58.37% to $155.4 million in 2023, then surged by 83.0% to $284.4 million in 2024, then grew by 11.16% to $316.1 million in 2025.
  • Its Total Debt stands at $316.1 million for Q3 2025, versus $307.0 million for Q2 2025 and $296.3 million for Q1 2025.